Menu

 

Research News

Apixaban strengthens its case in atrial fibrillation

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e6731 (Published 10 October 2012)
Cite this as: BMJ 2012;345:e6731

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Lancet 2012; doi:10.1016/S0140-6736(12)60986-6

Apixaban is an oral anticoagulant that inhibits factor Xa. It is one of a clutch of new oral agents competing with warfarin as a first line treatment for people with atrial fibrillation. Drug trials have established that apixaban prevents more thrombotic events than warfarin and is associated with …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Subscribe

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

Latest comments and most commented

THIS WEEK'S POLL

Read related article

See previous polls